Shared on05 Sep 25
HUTCHMED (China)’s valuation outlook has improved with a notable drop in its future P/E ratio from 35.13x to 26.14x while net profit margin held steady, resulting in no change to the consensus analyst price target, which remains £3.62. What's in the News Dr. Weiguo Su takes medical leave as CEO; CFO Johnny Cheng appointed Acting CEO while retaining CFO role.